Stock report · Delisted · Nasdaq
FibroGen Inc (FGEN)
9.22USD Delisted Final close · Jan 9, 2026
FGEN no longer trades. FibroGen was delisted from the Nasdaq in January 2026.
All prices on this page are historical. The last trade was on January 9, 2026, at $9.22.
FGEN stock price history
Final trading statistics
- Final close
- $9.22
- Final trading day
- Jan 9, 2026
- Market cap at delisting
- $37.30M
- Shares outstanding
- 4.05M
- Final 52-week range
- $0.23 – $12.60
- Avg. volume (final 3 mo.)
- 33,037
- All-time high
- $1681.25 · Jul 2018
- All-time low
- $5.16 · Jun 2025
- Return since IPO
- -98.3%
- Beta
- 0.77
- Book value / share
- −$4.21
- Price / book
- -2.19
About FibroGen Inc
FibroGen, Inc. was a biopharmaceutical company that discovered, developed and sold treatments for serious unmet medical needs. Its lead candidate, Roxadustat, a small molecule HIF prolyl hydroxylase inhibitor, had completed Phase III work for anemia in chronic kidney disease in China, Europe, Japan and elsewhere, and was in Phase III for anemia linked to myelodysplastic syndromes.
Its pipeline also included FG-3165 and FG-3175, an anti-GAL-9 antibody for solid tumors. It had collaboration deals with Astellas Pharma Inc. and AstraZeneca AB. Incorporated in 1993 and based in San Francisco, California, the company was delisted from the Nasdaq in January 2026, last trading on January 9, 2026 at $9.22.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Francisco, CA
- Employees
- 225
- IPO date
- November 14, 2014
- Delisted
- January 9, 2026
- SEC CIK
- 921299
FibroGen financials before the delisting
The last 5 fiscal years FibroGen reported as a public company, fiscal year ending December.
FGEN revenue and net income
FGEN earnings per share
FGEN annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $29.62M | −$47.6M | −$0.56 |
| FY2023 | $46.80M | −$284.2M | −$2.80 |
| FY2022 | $140.73M | −$293.7M | −$3.14 |
| FY2021 | $235.31M | −$291.0M | −$3.14 |
| FY2020 | $176.32M | −$189.3M | −$2.13 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
FibroGen stock FAQ
What happened to FibroGen stock?
FibroGen was delisted from the Nasdaq in January 2026. The final close was $9.22 on January 9, 2026.
Can I still buy FGEN stock?
No. FGEN is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on January 9, 2026.
What was the last price of FGEN?
FGEN last closed at $9.22 on January 9, 2026, which valued the company at about $37.30M.
How did FibroGen do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, FibroGen reported revenue of $29.62M and net income of −$47.6M.
When did FibroGen go public?
FibroGen shares started trading on November 14, 2014.
FGEN no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.